Nektar Therapeutics (NASDAQ:NKTR) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Nektar Therapeutics witnessed volume of 4.38 million shares during last trade however it holds an average trading capacity of 1.24 million shares. NKTR last trade opened at $6.17 reached intraday low of $6.15 and went +6.84% up to close at $6.72.
NKTR has intra-day market capitalization $768.94 million and an enterprise value at $732.66 million. Trailing twelve months price to sales ratio of the stock was 7.13 while price to book ratio in most recent quarter was 3.12. In profitability ratios, net profit margin in past twelve months appeared at -117.87% whereas operating profit margin for the same period at -96.46%.
The company made a return on asset of -10.59% in past twelve months and return on equity of 0.94% for similar period. In the period of trailing 12 months it generated revenue amounted to $101.01 million gaining $0.94 revenue per share. Its year over year, quarterly growth of revenue was -28.60%.
According to preceding quarter balance sheet results, the company had $266.49 million cash in hand making cash per share at 2.33. The total of $230.21 million debt was there putting a total debt to equity ratio 99.74. Moreover its current ratio according to same quarter results was 1.07 and book value per share was 2.02.
Looking at the trading information, the stock price history displayed that its S&P500 52 Week Change illustrated -0.46% where the stock current price exhibited up beat from its 50 day moving average price of $5.40 and remained above from its 200 Day Moving Average price of $5.51.
NKTR holds 114.43 million outstanding shares with 95.49 million floating shares where insider possessed 6.87% and institutions kept 90.20%.
